
Opinion|Videos|November 12, 2024
New Data from AANEM 2024 in Generalized Myasthenia Gravis
Key Takeaways
- Gene therapy advancements for inherited neuromuscular disorders were a significant focus, highlighting potential transformative impacts on treatment paradigms.
- Novel pharmacological interventions targeting specific molecular pathways showed promise, indicating a shift towards more targeted therapeutic approaches.
Panelists discuss how recent data presented at the 2024 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) conference may impact clinical practice for myasthenia gravis, highlighting emerging treatments they find particularly promising for future management of the condition.
Advertisement
Video content above is prompted by the following:
- Please share other interesting/practice-impacting data that were presented at AANEM 2024.
- What other emerging treatments are you excited about?
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Supplemental New Drug Application Submitted for AXS-05 as Treatment for Alzheimer Disease Agitation
2
ALS Qualitative Study Highlights Complexities of Decision-Making Process for Medical Aid in Dying (MAID)
3
Neflamapimod Phase 3 Trial in DLB, Troriluzole Gets CRL for SCA, Periodontal Disease and Stroke Risk
4
Real-World Oxybate Use in Narcolepsy, Tolerability and Reduced Stimulant Dependence
5


































